XNW-29016

Objectives of Phase I Study Main Objective: To evaluate the safety and tolerability of XNW29016 tablets in subjects with advanced solid tumors who have failed standard treatment, and to determine the maximum tolerated dose (MTD) of XNW29016 tablets, as well as the recommended dose (RP2D) for Phase II clinical studies. Secondary Objectives: To evaluate the pharmacokinetic (PK) characteristics of XNW29016 tablets and its metabolites in subjects with advanced solid tumors who have failed standard treatment; To evaluate the pharmacodynamic (PD) characteristics of XNW29016 tablets in subjects with advanced solid tumors who have failed standard treatment; To evaluate the preliminary efficacy of XNW29016 tablets in the treatment of subjects with advanced solid tumors who have failed standard treatment. Exploratory Objectives: To analyze the correlation between HRR pathway genes such as BRCA1/2, biomarkers such as HRD and efficacy. Purpose of Phase II Study Main Objective: To evaluate the anti-tumor efficacy of XNW29016 tablets in subjects with target indications. Secondary purpose: To evaluate the safety and tolerability of XNW29016 tablets in subjects with target indications; To evaluate the PK characteristics of XNW29016 tablets and its metabolites in subjects with target indications. Exploratory purpose: To analyze the correlation between HRR pathway genes such as BRCA1/2 and biomarkers such as HRD and efficacy.